Zheng Xia

Associate Professor

University of Texas at Austin
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (24)

Small-cell neuroendocrine carcinoma (SCNC) is a rare but highly malignant tumor subtype that primarily arises in the lung, also rarely in other organs, and as a consequence of treatment induced lineage transdifferentiation of prostate adenocarcinomas. The molecular convergence of SCNC across diverse tissues enables its identification through conserved SCNC-specific molecular markers, facilitating tumor subtype classification. As a critical post-transcriptional regulatory mechanism, alternative polyadenylation (APA) modulates 3′UTR length and significantly impacts tumor progression. However, its role in SCNC remains largely unclear. Here, we report a global 3′UTR lengthening pattern driven by APA in SCNC. We identified a set of conserved 3′UTR lengthening events across SCNCs of different tissue origins, which are strongly associated with neural development and related signaling pathways. Furthermore, we developed a neural network-based prediction model to classify SCNC by leveraging these specific APA signatures. Our study provides new insights into the post-transcriptional landscape of SCNCs and highlights APA signatures as promising biomarkers for SCNC identification.

Year:

2026

Low or absent expression of MHC on tumor cells is a presumed mechanism of resistance to immunotherapy, but evidence for this has largely been indirect. Likewise, whether immunotherapy can be effective without tumor MHC expression is also poorly understood. Using genetically engineered mouse tumor cells expressing the model neoantigen ovalbumin, we found that MHC class I–deficient tumor cells, but not MHC class I–sufficient tumor cells, grew progressively when injected subcutaneously into syngeneic C57BL/6 mice. However, combination immunotherapy using agonistic anti-CD40 and dual immune checkpoint blockade (anti–PD-1 and anti–CTLA-4) was equally effective against tumors that did not express the MHC class I H-2K b allele, MHC class II, or IFNγ receptor across multiple pancreatic tumor lines (regardless of ovalbumin). Moreover, CD4 + T cells, but not CD8 + T cells or perforin, were necessary to mediate immunotherapeutic responses. We excluded a role for CD4 + T cell–instructed macrophage-mediated tumor cell death but observed reprogramming of MHC class II–expressing stromal cells within the tumor after anti-CD40/ICB treatment. These data indicate that cancer immune surveillance by T cells does not absolutely require tumor-expressed MHC class I nor CD8 + T cells but instead can facilitate a clinically relevant remodeling of endothelial cells, further underscoring tumor-extrinsic roles for CD4 + T cells as mediators of tumor rejection and durable immune memory.

Year:

2026

DNA double-strand break (DSB) repair via homologous recombination (HR) is critical for maintaining genomic integrity and requires proper DNA end resection to generate single-stranded DNA (ssDNA) overhangs. However, the mechanisms governing this critical step in cells remains poorly understood. Here, we report that GNL3, a nucleolar GTP-binding protein, plays a key role in HR repair via regulating DNA end resection dependently on its SUMOylation. Ectopic expression of wild-type, but not the SUMO-defective K196R mutant, GNL3 completely abolished DNA damage response induced by knockdown of endogenous GNL3. GNL3 interacts with the BLM-DNA2 helicase-nuclease complex and is critical for DNA end resection and subsequent loading of RPA and RAD51. This interaction requires SUMOylation and SUMO-interacting motifs (SIMs) in both proteins. We further demonstrate that USP36, a nucleolar deubiquitinating enzyme, functions as a novel SUMO ligase for GNL3, while the SUMO protease SENP3 deSUMOylates GNL3. Notably, several breast cancer-derived GNL3 variants that disrupt its SUMOylation or SIM fail to interact with the BLM-DNA2 complex. Knockdown of GNL3 sensitizes HR-proficient breast cancer cells to etoposide or Olaparib treatment. Together, our results reveal that GNL3 SUMOylation is crucial for HR repair and suggest that targeting GNL3 SUMOylation may induce HR deficiency, thereby sensitizing breast cancers to DNA damage-inducing agents.

Year:

2025

Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunosuppressive tumor microenvironment (TME) and poor prognosis. While major histocompatibility complex class II (MHC-II) expression is traditionally associated with professional antigen-presenting cells, its role in PDAC malignant cells remains underexplored. Herein, we utilized single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, bulk RNA sequencing, multiplex immunohistochemistry (mIHC) and ex vivo studies in culture with both human and murine models to investigate the prognostic relevance of MHC-II expression in malignant PDAC cells. Elevated MHC-II expression in malignant cells was strongly associated with increased infiltration of CD4 + T and CD8 + T cells in human PDAC, and pronounced co-localization with plasma cells, indicative of an antigen-activated immune microenvironment. In the KPC mouse model of PDAC, pharmacologic induction of MHC-II expression by cobimetinib treatment in malignant epithelial cells significantly enhanced the therapeutic response to immune checkpoint blockade (ICB). These findings highlight the role of malignant cell- intrinsic MHC-II expression in promoting antigen presentation and fostering an anti-tumor immune microenvironment. Our results position MHC-II as a promising prognostic biomarker and therapeutic target in PDAC, paving the way for novel immunomodulatory strategies. Summary of highlights Single-cell and spatial transcriptomic analyses reveal that elevated MHC-II expression in malignant PDAC cells correlates with increased infiltration of CD4⁺ and CD8⁺ T cells. Stimulating MHC-II expression in tumors effectively enhances immunotherapeutic responses to ICB in the PDAC KPC mouse model, including PDAC tumors previously resistant to therapeutic interventions. MHC-II serves as a prognostic biomarker and a promising target for immunotherapy in PDAC.

Year:

2025

During prolonged starvation and exhaustive exercise, when there is low availability of carbohydrates, the liver breaks down fatty acids to generate ketone bodies, which are utilized by peripheral tissues as an alternative fuel source. The transcription factor MEF2D undergoes regulated alternative splicing in the postnatal period to produce a highly conserved, muscle specific MEF2Dα2 protein isoform. Here, we discover that compared to WT mice, MEF2Dα2 exon knockout (Eko) mice display reduced running capacity and muscle expression of all three ketolytic enzymes: BDH1, OXCT1, and ACAT1. MEF2Dα2 Eko mice consistently show increased blood ketone body levels in a tolerance test, after exercise, and when fed a ketogenic diet. Lastly, using mitochondria isolated from skeletal muscle, Eko mice show reduced ketone body utilization compared to WT mice. Collectively, our findings identify a new role for the MEF2Dα2 protein isoform in regulating skeletal muscle ketone body oxidation, exercise capacity, and systemic ketone body levels.

Year:

2025

WT EVs directly alter endothelial cell transcriptome, migration, barrier function, and tube formation. A, HPaMECs were treated with WT vs. HuR-KO EVs for 24 hours before RNA-seq and phenotypic assessment of migration, monolayer permeability, and tube formation. B, Volcano plot of differentially expressed genes in HPaMECs treated with PANC-1 HuR WT (blue, left) vs. HuR-KO (orange, right) EVs for 24 hours ( n = 3). C, Gene Ontology biological process analysis of the top seven pathways enriched in WT EV–treated and the top five pathways enriched in HuR-KO EV–treated HPaMECs ( n = 3). D, Transwell migration of HPaMECs treated with PANC-1 WT vs. HuR-KO EVs over 24 hours and quantified with crystal violet staining ( n = 3). Functional analysis of HPaMECs treated with media alone, PANC-1 WT, or HuR-KO EVs for 24 hours and monitored for ( E ) monolayer permeability quantified by dextran movement across the endothelial cell monolayer and ( F ) representative phase-contrast tube formation images with full field of view and region of interest (scale bar, 250 µm). G, Tube formation quantification for total tube length (px), total branching points, and total loops ( n = 3). P values were calculated using an unpaired two-tailed Student t test. *, P P P

Year:

2025

HuR affects PDAC EV cargoes relating to endothelial cell functions. A, Schematic of EV isolation from PANC-1 WT vs. HuR-KO cells for EV validation, RNA-seq, and proteomics. B, Immunoblot of cell lysates (CL) and SEC fractions 3–6 (pre-EV), 7–10 (EV), and 11–14 (post-EV) from PANC-1 WT (HuR status +) and HuR-KO (HuR status −) cells. Blot probed for total protein (Ponceau), HuR, EV markers (TSG101 and CD81), and cell lysate control (cytochrome c). C, Electron microscopy validation of SEC fractions 7–10 (scale bar, 50 nm). D, Mean particle size and concentration normalized to final cell number measurements via fluorescent nanoparticle tracking analysis. P values were calculated using an unpaired two-tailed Student t test ( n = 4). E, RNA-seq volcano plot of differentially abundant genes in WT (blue, left) vs. HuR-KO (orange, right) EVs ( n = 4). F, RNA-seq pathway enrichment analysis highlighting the top nine enriched pathways in WT EVs (blue) and the top four enriched pathways in HuR-KO EV mRNA (orange). G, Volcano plot isobaric-labeling quantitative proteomics illustrating the differentially abundant proteins in WT (blue, left) vs. HuR-KO (orange, right) EVs ( n = 3). H, Proteomics pathway enrichment analysis highlighting the top nine enriched pathways in WT EVs (blue) and the top four enriched pathways in HuR-KO EV proteins (orange). ER, endoplasmic reticulum; ns, not significant; PDT, photodynamic therapy; OvCa, ovarian cancer; UPS, unfolded protein response.

Year:

2025

Pancreatic ductal adenocarcinoma (PDAC) tumors are hypovascular with collapsed and dysfunctional vessels that limit immunosurveillance and contribute to early metastatic events. However, current antiangiogenic therapies have failed in PDAC, highlighting the need to uncover the mechanisms by which cancer cells signal to endothelial cells to increase angiogenesis. Our lab has shown that the tumor-intrinsic RNA-binding protein human antigen R (HuR; ELAVL1 ) plays an important role in reshaping the tumor microenvironment by regulating the stability and translation of cell communication–encoding transcripts. We demonstrate that PDAC-intrinsic HuR influences endothelial cell function in the tumor microenvironment via extracellular vesicle (EV) signaling, an underexplored signaling axis in tumor progression. PDAC EVs contain an HuR-dependent mRNA and protein cargo related to endothelial cell function and angiogenesis. Treating endothelial cells with HuR wild-type (WT) EVs increased the expression of genes involved in barrier function and endothelial cell development and increased their migratory and tube-forming functions. In an immunocompetent mouse model of PDAC, we showed that HuR increased endothelial cell presence and sprouting, while decreasing intercellular adhesion molecule 1 (ICAM-1) expression. Using a genetic EV reporter, we found that ICAM-1 suppression in WT tumors occurred specifically in endothelial cells that had internalized WT EVs, suggesting that this signaling axis modulates endothelial cell behavior in vivo . Furthermore, administration of WT EVs rescued impaired HuR-knockout tumor growth, increased endothelial cell abundance, and decreased endothelial cell ICAM-1 expression. Collectively, our data reveal a novel role for HuR as a key mediator of EV signaling to endothelial cells, promoting angiogenesis while restricting endothelial cell leukocyte trafficking behavior. Significance: Targeting the abnormal pancreatic cancer vasculature remains a significant barrier to immunosurveillance and drug delivery. This study demonstrated that the tumor-intrinsic protein HuR regulates pancreatic cancer EVs, which, in turn, alters endothelial cell behavior. These findings reveal a novel mechanism by which tumor-intrinsic factors shape the vascular microenvironment and suggest that altering EV content could modulate endothelial cell function.

Year:

2025

Tumor-intrinsic HuR directly alters endothelial cell function via EV signaling. A, Schematic of the PalmGRET reporter labeling the inner leaflet of all membranes with GFP-nLuc via integration of a palmitoylation sequence. The construct for the PalmGRET EV reporter labels the inner leaflet of all cellular membranes and secreted membranous particles. B, PalmGRET-expressing cells produce GFP + EVs detected by fluorescent nanoparticle tracking analysis ( n = 3). C, Cell growth of PalmGRET-expressing KPC cells over 6 days. D, Immunoblot of cell lysates utilized for mouse studies probed for HuR, nLuc, and loading control vinculin. E, PalmGRET-expressing cells were orthotopically implanted into C57BL6 mice, and tumors were harvested at 14 days for flow cytometry. Levels of EV import (GFP MFI) in endothelial cells (CD45 − CD31 + ) were equal in WT and HuR-KO tumors ( n = 7). F, Total endothelial cell (CD45 − CD31 + ) presence as quantified by cells per gram of tumor in WT vs. HuR-KO tumors ( n = 7). G, ICAM-1 geometric mean surface expression of ICAM-1 in endothelial cells (CD45 − CD31 + ) of WT vs. HuR-KO tumors ( n = 7). H, ICAM-1 geometric mean surface expression (MFI) of ICAM-1 in endothelial cells of WT vs. HuR-KO tumors that have (GFP + ) or have not (GFP − ) imported PDAC EVs ( n = 7). P values were calculated using an unpaired two-tailed Student t test or an ordinary one-way ANOVA ( H only). *, P P P

Year:

2025

HuR WT EVs are tumor promoting and directly decrease ICAM-1 expression on endothelial cells. A, Schematic of EV isolation from KPC WT and HuR-KO cells via SEC. B, Immunoblot of cell lysates (CL) and SEC fractions 1, 7–10 (EV containing), and 14 from KPC WT (HuR status +) and HuR-KO (HuR status −) cells. Blot probed for total protein (Ponceau), HuR, EV markers (TSG101 and CD81), and cell lysate control (cytochrome c). C, Particle size concentration normalized to final cell number measurements via fluorescent nanoparticle tracking analysis. ( n = 4). D, Schematic of pancreatic orthotopic implantation of KPC KO cells into C57BL6 mice following intraperitoneal injection of WT vs. HuR-KO EVs every other day for 14 days and ( E ) tumor volume (mm 3 ) after 14 days (WT EV n = 6; HuR-KO EV n = 5). IF staining for ( F ) proliferation (Ki-67, magenta; n = 5), ( G ) endothelial cells (endomucin, magenta; WT EV n = 5 and HuR-KO EV n = 8), and ( H ) co-staining of endothelial cells (endomucin, magenta) and ICAM-1 (white; WT EV n = 6 and HuR-KO EV n = 7; scale bar, 100 µm). P values were calculated using an unpaired two-tailed Student t test. *, P P P

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Collaborators (34)

Thomas O'Loughlin

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Robert H. Vonderheide

University of Pennsylvania

UNITED STATES
View details

Davide Ruggero

Professor

University of California

UNITED STATES
View details

Canping Chen

Oregon Health & Science University

UNITED STATES
View details

Gordon Mills

Professor

Oregon Health & Science University

UNITED STATES
View details

David A. Quigley

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Robert Eil

Assistant Professor

Oregon Health & Science University

UNITED STATES
View details

Rosalie C. Sears

Professor; Co-Director Brenden Colson Center for Pancreatic Care

Oregon Health & Science University

UNITED STATES
View details

Katelyn Byrne

Assistant Professor

Oregon Health & Science University

UNITED STATES
View details

Wilbert Zwart

Senior Groupleader / professor

Eindhoven University of Technology

NETHERLANDS
View details

Luke Gilbert

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Alan Ashworth

University of California, San Francisco

UNITED STATES
View details

Ranjan K Dash

Professor

Medical College of Wisconsin

UNITED STATES
View details

Seung Kim

KM Mulberry Professor

Stanford University

UNITED STATES
View details

Jonathan R. Brody

Oregon Health & Science University

UNITED STATES
View details

Ravi Singh

Assistant Professor

University of Houston

UNITED STATES
View details

Adam Sowalsky

Senior Investigator

National Cancer Institute

UNITED STATES
View details

Michelle Badura

Lecturer

Santa Clara University

UNITED STATES
View details

Duygu Kuzuoglu Ozturk

Assistant Prof

Sabancı University

TURKEY
View details

Raunak Shrestha

Assistant Professor

Uniformed Services University of the Health Sciences

UNITED STATES
View details

Chet Oon

Oregon Health & Science University

UNITED STATES
View details

Mara H. Sherman

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

George V Thomas

Professor of Pathology & Laboratory Medicine

Oregon Health & Science University

UNITED STATES
View details

Mu-Shui Dai

Oregon Health & Science University

UNITED STATES
View details

Lawrence Fong

Fred Hutch Cancer Center

UNITED STATES
View details

Matthew R. Cooperberg

University of California

UNITED STATES
View details

Pepper Schedin

Professor

Oregon Health & Science University

UNITED STATES
View details

Aaron Grossberg

Associate Professor

Oregon Health & Science University

UNITED STATES
View details

Arian Lundberg

Assistant Professor at KTH Royal Institute of Technology

KTH Royal Institute of Technology

SWEDEN
View details

Felix Y. Feng

University of California

UNITED STATES
View details

Hen Halamish

Oregon Health & Science University

UNITED STATES
View details

Peter S. Nelson

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Valerie Calvert

Research Assistant Professor

George Mason University

UNITED STATES
View details

Jessica Hawley

Assistant Professor

University of Washington

UNITED STATES
View details